The dynamic nearest neighbor policy for the multi-vehicle pick-up and delivery problem

In this paper, a dynamic nearest neighbor (DNN) policy is proposed for operating a fleet of vehicles to serve customers, who place calls in a Euclidean service area according to a Poisson process. Each vehicle serves one customer at a time, who has a distinct origin and destination independently and uniformly distributed within the service area. The new DNN policy is a refined version of the nearest neighbor (NN) policy that is well known to perform sub-optimally when the frequency of customer requests is high. The DNN policy maintains geographically closest customer-to-vehicle assignments, due to its ability to divert/re-assign vehicles that may be already en-route to pick up other customers, when another vehicle becomes available or a new customer call arrives. Two other pertinent issues addressed include: the pro-active deployment of the vehicles by anticipating in which regions of the service area future calls are more likely to arise; and, imposition of limits to avoid prohibitively long customer wait times. The paper also presents accurate approximations for all the policies compared. Extensive simulations, some of which are included herein, clearly show the DNN policy to be tangibly superior to the first-comefirst-served (FCFS) and NN policies

Task Re-allocation Methodologies for Teams of Autonomous Agents in Dynamic Environments

Two on-line task re-allocation methodologies capable of re-allocating agents to tasks on-line for minimum task completion time in dynamic environments are presented herein. The first methodology, the Dynamic Nearest Neighbour (DNN) Policy, is proposed for the operation of a fleet of vehicles in a city-like application of the dial-a-ride problem. The second methodology, the Dynamic Re-Pairing Methodology (DRPM) is proposed for the interception of a group of mobile targets by a dynamic team of robotic pursuers, where the targets are assumed to be highly maneuverable with a priori unknown, but real-time trackable, motion trajectories. Extensive simulations and experiments have verified the DNN policy to be tangibly superior to the first-come-first-served and nearest neighbour policies in minimizing customer mean system time, and the DRPM to be tangibly efficient in the optimal dynamic re-pairing of multiple mobile pursuers to multiple mobile targets for minimum total interception time.MAS

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo